Searched over 200M research papers
10 papers analyzed
These studies suggest lisinopril begins to reduce blood pressure within 4 hours after initial administration.
20 papers analyzed
Lisinopril, an ACE inhibitor, is commonly used to manage hypertension. The antihypertensive effect of lisinopril begins within 2 hours of oral administration, peaks around 6 hours, and lasts for at least 24 hours . This gradual onset ensures a smooth reduction in blood pressure without significantly affecting heart rate or cardiovascular reflexes.
Lisinopril is orally active and reaches peak serum concentrations 6-8 hours after dosing . Its bioavailability is approximately 25%, and it is not significantly affected by food intake . The drug is excreted unchanged in the urine, and steady-state concentrations are achieved within 2-3 days of consistent dosing .
In the context of acute myocardial infarction (AMI), lisinopril has shown significant benefits when administered within 24 hours of symptom onset. The GISSI-3 trial demonstrated measurable survival benefits within 1 to 2 days of starting treatment, with reductions in mortality and severe left ventricular dysfunction . This early intervention is crucial for high-risk patients, including those with diabetes or left ventricular dysfunction .
For patients with congestive heart failure, lisinopril produces maximum pharmacodynamic effects 6 to 8 hours after administration, with benefits persisting for 12 to 24 hours. High doses of lisinopril have been shown to reduce the risk of major clinical events and hospitalizations more effectively than low doses.
In hypertensive patients with acute ischemic stroke, lisinopril has been found to significantly lower blood pressure within 4 hours of the first dose. This reduction is maintained with daily dosing, demonstrating its efficacy as a hypotensive agent in acute settings.
Lisinopril begins to lower blood pressure within 2 hours of administration, with peak effects observed around 6 hours. Its benefits extend beyond hypertension management to improving outcomes in acute myocardial infarction and congestive heart failure. The drug's consistent and gradual action makes it a reliable choice for various cardiovascular conditions.
Most relevant research papers on this topic